IsoPlexis Targets New Market Segments With Cheaper, More Flexible Single-Cell Proteomic Systems

IsoPlexis Targets New Market Segments With Cheaper, More Flexible Single-Cell Proteomic Systems

Single-cell proteomics firm IsoPlexis is looking to expand its market reach with the launch of a lower-priced, smaller-footprint platform and new assay capabilities. The company also continues to move its technology into the clinic, having identified a blood-based biomarker of response to immunotherapy in melanoma that researchers presented on at the Society for Immunotherapy of Cancer (SITC) annual meeting this month. The IsoSpark has an 18-inch footprint and can run four chips at a time compared to eight chips simultaneously for the IsoLight system. Mackay added that the platform is targeted to the academic and biotech markets, which he said “prefer having more modular, personalized lab systems.” IsoPlexis also launched this month the IsoSpark Duo, which is more targeted to the IsoLight user base, offering the same level of throughput but increased flexibility in that it can run two different sets of chips simultaneously, allowing researchers to profile different cell types in the same experiment.